© Reuters. FILE PHOTO: The logo of Sanofi is seen a the French drugmaker's vaccine unit Sanofi Pasteur plant in Marcy-l'Etoile, near Lyon, France, September 30, 2023. REUTERS/Gonzalo Fuentes/File PhotoDeliberations are ongoing and there is no certainty they will result in an agreement, the report said, adding that Mirati could also attract interest from other suitors.
The U.S. health regulator had in December approved Mirati's lung cancer drug, Krazati, to treat adults with advanced lung cancer. In November last year, Bloomberg had reported that Mirati was drawing takeover interest from large pharmaceutical companies.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: